OncoMatch/Clinical Trials/NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Is NCT06487624 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HCB301 for advanced solid tumor.
Treatment: HCB301 — The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
classical Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of systemic therapy
Cannot have received: SIRPα-CD47 pathway inhibitor
Have received any treatment targeting the SIRPα-CD47, PD-L1, or TGF-β pathway
Cannot have received: PD-L1 pathway inhibitor
Have received any treatment targeting the SIRPα-CD47, PD-L1, or TGF-β pathway
Cannot have received: TGF-β pathway inhibitor
Have received any treatment targeting the SIRPα-CD47, PD-L1, or TGF-β pathway
Cannot have received: systemic cancer therapy
Any investigational or approved systemic cancer therapy administered within 21 days or 5 half-lives, whichever is shorter, before the first dose of the study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Prisma Health-Upstate · Greenville, South Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06487624 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior SIRPα-CD47 pathway inhibitor, PD-L1 pathway inhibitor, TGF-β pathway inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages